Colin Haile, MD, PhD is a physician–scientist and addiction researcher specializing in the development of innovative biologic and pharmacologic treatments for substance use disorders. He is an inventor of the ARMR-100 program, a next-generation immunotherapy platform designed to neutralize synthetic opioids before they reach the brain.

Dr. Haile currently serves as a Research Associate Professor of Psychology at the University of Houston, with appointments at the Texas Institute for Measurement, Evaluation, and Statistics (TIMES). He is also a founding member of the University of Houston Drug Discovery Institute, where he collaborates across disciplines to accelerate translational drug development.

His research integrates neuroscience, behavioral pharmacology, and controlled human laboratory models to evaluate novel therapeutics for opioid, cocaine, and methamphetamine use disorders. Dr. Haile has led and contributed to federally funded studies advancing monoclonal antibodies, vaccines, and other biologically based approaches aimed at reducing drug craving, preventing relapse, and mitigating overdose risk.

Through his leadership on the ARMR-100 program and his academic work at the University of Houston, Dr. Haile focuses on translating cutting-edge addiction science into scalable, clinically deployable countermeasures to address the growing synthetic drug crisis.